Evidence map›Paper›PMID 40078729›Full record

ArticleBiosafety and health2024

Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis.

Minghui Li, Weihua Cao, Tingting Jiang, Wen Deng, Shiyu Wang, Shuling Wu, Lu Zhang, Yao Lu, Min Chang, Ruyu Liu and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biosafety and health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Weihua CaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Tingting JiangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Shuling WuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Lu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yao LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Min ChangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Ruyu LiuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xiaoyan DingDepartment of Medical Oncology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Ge ShenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yuanjiao GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Hongxiao HaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xiaoxue ChenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Leiping HuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Mengjiao XuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yuyong JiangCenter of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Wei YiDepartment of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Rui SongDepartment of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (

Indexed as

Autoimmune hepatitis (AIH)Autoimmune liver disease (AILD)Coronavirus disease 2019 (COVID-19)Primary biliary cholangitis (PBC)Ursodeoxycholic acid (UDCA)

Identifiers

PMID40078729
PMCPMC11895010

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.